Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients

Ann Oncol. 2017 Dec 1;28(12):3104-3106. doi: 10.1093/annonc/mdx538.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / immunology
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / immunology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Merkel Cell / drug therapy*
  • Carcinoma, Merkel Cell / immunology
  • Carcinoma, Merkel Cell / virology
  • Female
  • HIV Infections / immunology*
  • Humans
  • Ipilimumab / administration & dosage
  • Ipilimumab / adverse effects
  • Ipilimumab / immunology
  • Ipilimumab / therapeutic use
  • Male
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Melanoma / virology
  • Middle Aged
  • Nivolumab
  • Retrospective Studies
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / immunology
  • Skin Neoplasms / virology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Ipilimumab
  • Nivolumab
  • pembrolizumab